FHL3 Regulates Vascular Smooth Muscle Cell Phenotypic Switching Through the MRTFB-SRF Signaling Axis
Open Access
Abstract
Genome-wide association studies have uncovered many coronary artery disease (CAD) loci, but mechanisms linking risk variants to vascular biology remain unclear. We screen candidate causal CAD genes for regulators of the vascular smooth muscle cell (VSMC) contractile phenotype using a pooled CRISPR–Cas9 knockout library in primary human VSMCs with MYH11 protein levels as the readout. FHL3 (four-and-a-half LIM domains protein 3) emerges as the top repressor of the contractile state. Colocalization analyses in a VSMC biobank and vascular tissues associate a CAD risk allele with reduced FHL3 expression. Biochemical and imaging studies show FHL3 is associated and co-localizes with the transcriptional co-activator MRTFB (myocardin-related transcription factor-B). Functionally, FHL3 overexpression attenuates MRTFB-serum response factor (SRF)-driven induction of contractile markers (MYH11, transgelin), whereas FHL3 knockdown increases their expression in an MRTFB-dependent manner. FHL3 knockdown or MRTFB overexpression reduces VSMC proliferation and migration, and FHL3 overexpression mitigates MRTFB-driven effects on these behaviors. These data identify FHL3 as a regulator of VSMC plasticity that inhibits the contractile phenotype by interfering with MRTFB-SRF signaling, link a CAD-associated genetic signal to the VSMC phenotype, and nominate the FHL3-MRTFB interaction as a potential therapeutic target.Keywords
Funding Information
- National Medical Research Council (MOH-001229)
- National Medical Research Council (MOH-001479)
- National University of Singapore/National University Health System (NUHSRO/2022/004/Startup/01)
- Leicester British Heart Foundation Accelerator Award (AA/18/3/34220)
- British Heart Foundation Research Excellence Award (RE/24/130031)
- Van Geest Foundation Heart and Cardiovascular Diseases Research Fund
- BHF Accelerator Early Careers Researcher Interdisciplinary Fellowship
- British Heart Foundation (RG/16/13/32609)
- British Heart Foundation (RG/19/9/34655)
- British Heart Foundation (PG/16/9/31995)
- British Heart Foundation (PG/18/73/34059)
- British Heart Foundation (SP/19/2/344612)
This publication has 51 references indexed in Scilit:
- Integrative analysis of single-cell transcriptomics and genetic associations identify cell states associated with vascular diseaseAtherosclerosis, 2025
- Unraveling the role of the FHL family in cardiac diseases: Mechanisms, implications, and future directionsBiochemical and Biophysical Research Communications, 2024
- Isolation of Genomic DNA from Mammalian Cells and Fixed TissueCurrent Protocols, 2023
- FHL3 promotes the formation of fast glycolytic muscle fibers by interacting with YY1 and muscle glycolytic metabolismCellular and Molecular Life Sciences, 2023
- The Global Burden of Cardiovascular Diseases and RiskJACC, 2022
- FHL3 differentially regulates the expression of MyHC isoforms through interactions with MyoD and pCREBCellular Signalling, 2016
- ADAMTS7 Cleavage and Vascular Smooth Muscle Cell Migration Is Affected by a Coronary-Artery-Disease-Associated VariantThe American Journal of Human Genetics, 2013
- Deletion of the FHL2 gene attenuates the formation of atherosclerotic lesions after a cholesterol-enriched dietLife Sciences, 2010
- Myocardin-related transcription factors and SRF are required for cytoskeletal dynamics and experimental metastasisNature Cell Biology, 2009
- The LIM domain: a new structural motif found in zinc-finger-like proteinsTrends in Genetics, 1994